Peihao Zheng
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation.
Journal: Frontiers in oncology
Published: March 11, 2025
CD20CAR-T Therapy Preemptively Treats Patients with Relapsed/Refractory DLBCL in Partial Remission after CD19CAR-T.
Journal: Transplantation and cellular therapy
Published: February 16, 2025
Sequential CD19-20 CAR T-cell therapy for refractory/relapsed diffuse large B-cell lymphoma.
Journal: Cytotherapy
Published: January 08, 2025
BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review.
Journal: Critical reviews in oncology/hematology
Published: September 22, 2024
Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure.
Journal: Frontiers in oncology
Published: January 25, 2024
Efficacy and Safety of CART Cell Therapy in Aggressive B-Cell Lymphomas Involving the Gastrointestinal Tract.
Journal: Cancer reports (Hoboken, N.J.)
Published: December 15, 2023
Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.
Journal: Cancer medicine
Published: January 02, 2023
The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma.
Journal: Journal of oncology
Published: May 11, 2022
Last Updated: 09/26/2026